MY188689A - Gene therapy composition - Google Patents

Gene therapy composition

Info

Publication number
MY188689A
MY188689A MYPI2018701967A MYPI2018701967A MY188689A MY 188689 A MY188689 A MY 188689A MY PI2018701967 A MYPI2018701967 A MY PI2018701967A MY PI2018701967 A MYPI2018701967 A MY PI2018701967A MY 188689 A MY188689 A MY 188689A
Authority
MY
Malaysia
Prior art keywords
genes
gene therapy
apoptosis
therapy composition
inducing
Prior art date
Application number
MYPI2018701967A
Inventor
Tetsuyuki Hirahata
Original Assignee
Tetsuyuki Hirahata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetsuyuki Hirahata filed Critical Tetsuyuki Hirahata
Publication of MY188689A publication Critical patent/MY188689A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Problem: To provide a gene therapy composition, which gene therapy composition promotes cancer cell apoptosis by delivering apoptosis-inducing genes comprising a combination of multiple genes into cancer cells, and to a liposome vector for transferring the gene therapy composition to cancer cells and a method of preparing the liposome vector. Solution: A gene therapy composition comprising a gene therapy composition for preventing and/or treating cancer whose anti-tumor genes are apoptosis-inducing genes, wherein the apoptosis-inducing genes comprise p53 genes, FUS-1 genes, TRAIL genes and IL-24 genes. composition for preventing and/or treating cancer whose anti-tumor genesare apoptosis-inducing genes, wherein the apoptosis-inducing genes comprise p53 genes, FUS-1 genes, TRAIL genes and IL-24 genes. (Figure 1)
MYPI2018701967A 2015-10-23 2015-10-23 Gene therapy composition MY188689A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2015/005342 WO2017068614A1 (en) 2015-10-23 2015-10-23 Gene therapy composition

Publications (1)

Publication Number Publication Date
MY188689A true MY188689A (en) 2021-12-23

Family

ID=58557009

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018701967A MY188689A (en) 2015-10-23 2015-10-23 Gene therapy composition

Country Status (4)

Country Link
JP (1) JP6837984B2 (en)
MY (1) MY188689A (en)
SG (1) SG11201803940PA (en)
WO (1) WO2017068614A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102631802B1 (en) 2018-09-05 2024-01-31 엘지전자 주식회사 Method for encoding/decoding video signal, and apparatus therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047690A2 (en) * 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Multigene vectors

Also Published As

Publication number Publication date
JP6837984B2 (en) 2021-03-03
SG11201803940PA (en) 2018-06-28
WO2017068614A1 (en) 2017-04-27
JPWO2017068614A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
FIC20250001I1 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
IL260959A (en) Gene therapy for treating mucopolysaccharidosis type i
MX2024013018A (en) Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
MX2024007924A (en) Multiplexed genome editing.
GB2557123A (en) Modified cells and methods of therapy
IL258726B (en) Methods of preparing t cells for t cell therapy
IL271780A (en) Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
WO2016012544A3 (en) Enhanced reprogramming to ips cells
EP3260539A4 (en) Method for transferring cas9 mrna into mammalian fertilized egg by electroporation
MX368442B (en) Fusion protein inhibiting angiogenesis or growth and use thereof.
MX2017014163A (en) K-ras modulators.
MX2021014663A (en) Compound targeting il-23a and tnf-alpha and uses thereof.
EP3193944A4 (en) Methods of treating cells containing fusion genes
EP3342858A4 (en) Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells
EP3207377A4 (en) Circulating tumor cell diagnostics for therapy targeting pd-l1
IL267057A (en) Gene therapy for mucopolysaccharidosis, type i
EP3998341A3 (en) Adenoviral vectors
MX2018006527A (en) Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer.
IL267060A (en) Gene therapy for mucopolysaccharidosis, type ii
MX2020011500A (en) Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth.
EP3159403A4 (en) Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same
WO2013103836A3 (en) Methods of treating cancer
MX2014003094A (en) Methods of promoting differentiation.
MY188689A (en) Gene therapy composition
GB201803419D0 (en) Complex for the delivery of cas9 proteins guide RNA to cells